NEW YORK (GenomeWeb News) – Myriad Genetics and Cephalon have signed an agreement to conduct BRCA1 and BRCA2 mutation testing on patients to be enrolled in a Phase I/II clinical study, Myriad announced after the close of the market Wednesday.
Myriad said it will assess BRCA status in patients before they are enrolled in the study, but provided no other details about the study or Cephalon's candidate molecule. Financial and other terms of the agreement also were not disclosed.
Cephalon is a subsidiary of Teva Pharmaceutical Industries.
The Salt Lake City-based molecular diagnostics firm has other similar companion diagnostic deals with Abbott Laboratories, AstraZeneca, and BioMarin Pharmaceutical using the BRACAnalysis test for clinical trial enrollment.